Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine up-dosing vs bilastine + levocetirizine in chronic spontaneous urticaria
NCT07365683Completed
- Sponsor
- Derma Techno
- Start
- Aug 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bilastine in chronic spontaneous urticaria (CSU) (2 arms), sponsored by Derma Techno. Primary endpoint: Urticaria Activity Score over 7 days at 6 weeks. Started Aug 2025; status: completed.
02
Drugs
bilastine
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07365683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365683.